Small molecule · Antagonist of calcitonin gene-related peptide receptor (CALCRL) · developed by Abbvie
Ubrogepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist that blocks CGRP signaling at its receptor. It is used for the acute treatment of migraine with or without aura in adults.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Sep 29, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07680686 | Phase 1 | Healthy Volunteer | Completed | ABBV |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy Volunteer
Updated Nov 15, 2026. Something wrong or missing? Report it on the ABBV page.
See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ABBV catalysts and pipeline →